Kinetic considerations relating to the accrual and elimination of drug metabolites.
作者信息
Cummings A J, Martin B K, Park G S
出版信息
Br J Pharmacol Chemother. 1967 Feb;29(2):136-49. doi: 10.1111/j.1476-5381.1967.tb01947.x.
Abstract
摘要
相似文献
1
Kinetic considerations relating to the accrual and elimination of drug metabolites.
Br J Pharmacol Chemother. 1967 Feb;29(2):136-49. doi: 10.1111/j.1476-5381.1967.tb01947.x.
2
3
Kinetic considerations relating to the use of drug precursors.
Br J Pharmacol Chemother. 1967 Nov;31(3):420-34. doi: 10.1111/j.1476-5381.1967.tb00409.x.
4
Effects of induction of cytochrome P-450 enzymes on the concentration of foreign compounds and their metabolites and on the toxicological effects of these compounds.
Drug Metab Rev. 1979;10(1):59-87. doi: 10.3109/03602537908993901.
5
[Problems of pharmacokinetics].
Arzneimittelforschung. 1972 Feb;22(2):283-5.
6
Drug metabolism in the elderly.
Age Ageing. 1978;Suppl:131-3. doi: 10.1093/ageing/7.suppl.131.
7
Method for estimating rate constants for absorption, metabolism, and elimination from urinary excretion data.
J Pharm Sci. 1967 Apr;56(4):489-94. doi: 10.1002/jps.2600560413.
8
Therapeutic drug monitoring. Pharmacokinetics.
Am J Med Technol. 1983 Aug;49(8):557-63.
9
[Drug pharmacokinetics and pharmacodynamics in children].
Farmakol Toksikol. 1982 May-Jun;45(3):27-31.
10
How drugs act. Two. Elimination and cumulation.
Nurs Times. 1984;80(49):44-6.
引用本文的文献
1
Rationalization and prediction of in vivo metabolite exposures: the role of metabolite kinetics, clearance predictions and in vitro parameters.
Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1095-109. doi: 10.1517/17425255.2010.497487.
2
Pharmacokinetics of a nootropic agent, BMY-21502, and its metabolites in beagle dogs.
Eur J Drug Metab Pharmacokinet. 1998 Jan-Mar;23(1):61-5. doi: 10.1007/BF03189828.
3
The kinetics of the urinary excretion of the N-oxide and glucuronides of methaqualone in man.
Eur J Drug Metab Pharmacokinet. 1981;6(4):289-95. doi: 10.1007/BF03189528.
4
Metabolite pharmacokinetics: the area under the curve of metabolite and the fractional rate of metabolism of a drug after different routes of administration for renally and hepatically cleared drugs and metabolites.
J Pharmacokinet Biopharm. 1981 Aug;9(4):477-87. doi: 10.1007/BF01060890.
5
Genetically determined oxidation capacity and the disposition of debrisoquine.
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.
6
Drug metabolite concentration-time profiles: influence of route of drug administration.
Br J Clin Pharmacol. 1984 Apr;17(4):385-94. doi: 10.1111/j.1365-2125.1984.tb02362.x.
7
The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
Br J Clin Pharmacol. 1983 Aug;16(2):157-66. doi: 10.1111/j.1365-2125.1983.tb04980.x.
8
Assessment of drug metabolism in hepatic disease: comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test.
Eur J Clin Pharmacol. 1984;26(1):95-101. doi: 10.1007/BF00546715.
9
Kinetic considerations relating to the use of drug precursors.
Br J Pharmacol Chemother. 1967 Nov;31(3):420-34. doi: 10.1111/j.1476-5381.1967.tb00409.x.
10
Drug urinary excretion data--some aspects concerning the interpretation.
Br J Pharmacol Chemother. 1967 Feb;29(2):181-93. doi: 10.1111/j.1476-5381.1967.tb01951.x.
本文引用的文献
1
Kinetic studies of the metabolism of foreign organic compounds; the formation of benzoic acid from benzamide toluene, benzyl alcohol and benzaldehyde and its conjugation with glycine and glucuronic acid in the rabbit.
Biochem J. 1951 Jan;48(1):88-96. doi: 10.1042/bj0480088.
2
EXCRETION AND THE ACCRUAL OF DRUG METABOLITES.
Nature. 1963 Dec 28;200:1296-7. doi: 10.1038/2001296a0.
3
Excretion equations and interpretation for digitoxin.
Nature. 1957 Jan 12;179(4550):98-100. doi: 10.1038/179098b0.
Zotero 插件